Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gollob, M. H.
Right arrow Articles by Seger, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gollob, M. H.
Right arrow Articles by Seger, J. J.
(Chest. 2001;119:1210-1221.)
© 2001 American College of Chest Physicians

Current Status of the Implantable Cardioverter-Defibrillator*

Michael H. Gollob, MD and John J. Seger, MD

* From the Section of Cardiology (Dr. Gollob), Baylor College of Medicine, Houston, TX; Division of Cardiology (Dr. Seger), Texas Heart Institute, Houston, TX.

Correspondence to: Michael H. Gollob, MD, Section of Cardiology, RM 507D, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030; e-mail: mgollob{at}bcm.tmc.edu

Clinical trials have established the superiority of the implantable cardioverter-defibrillator (ICD) over antiarrhythmic drug therapy in survivors of sudden cardiac death and in high-risk patients with coronary artery disease. The ICD has evolved to overcome the limitation of earlier devices that required thoracotomy for implantation and were fraught with inappropriate shock delivery. Current ICDs are implanted in a similar manner to cardiac pacemakers and incorporate sophisticated rhythm-discrimination algorithms to prevent inappropriate therapy. Managing the patient with an ICD requires an understanding of the multiprogrammable features of modern devices. Drug interactions and potential sources of electromagnetic interference may adversely affect ICD function. Driving restrictions may be necessary under certain conditions. The cost-effectiveness of ICD therapy appears favorable, given the marked survival benefit seen in randomized trials relative to antiarrhythmic drug treatment. The growing number of ICD recipients necessitates an understanding of the specialized features of the modern ICD and the role of device therapy in clinical practice.

Key Words: implantable cardioverter-defibrillator • sudden cardiac death




This article has been cited by other articles:


Home page
 JAMAHome page
Z. Goldberger and R. Lampert
Implantable Cardioverter-Defibrillators: Expanding Indications and Technologies
JAMA, February 15, 2006; 295(7): 809 - 818.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. A. Driscoll and K. C. Sumino
BRONCHOMEDIASTINAL FISTULA CAUSED BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR EPICARDIAL PATCH ELECTRODE
Chest Meeting Abstracts, October 1, 2005; 128(4): 409S - 410S.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
I. R. Hanna and J. J. Langberg
The Shocking Story of Azimilide
Circulation, December 14, 2004; 110(24): 3624 - 3626.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Chest Physicians.